Science · Open for opinions
Will the FDA approve a new Phase 2 clinical trial for in vivo immunotherapy against multiple sclerosis by 10/31/2026?
Promising initial results of in vivo immune reprogramming against multiple sclerosis boost expectations for more advanced trials [4]. 15 opinions, 73% No
- Yes — 27%
- No — 73%
Deadline: October 31, 2026 at 11:59 PM UTC · 15 opinions
Resolution rules
Promising initial results of in vivo immune reprogramming against multiple sclerosis boost expectations for more advanced trials [4].
Source: www.nature.com
Frequently asked questions about this event
How is this event resolved?
Janela de apuração: de 03/09/2026 (00:00, horário de Brasília) até 31/10/2026 (23:59). Fatos, anúncios ou eventos anteriores ao início da janela não contam. Resolve como 'Sim' se a FDA (Food and Drug Administration) aprovar ou registrar autorização para ensaio clínico de Fase 2 de terapia celular/gênica in vivo voltada ao tratamento de esclerose múltipla até 31/10/2026, conforme divulgado na base oficial ClinicalTrials.gov ou comunicado no fda.gov. Caso contrário, resolve como 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 73% of the votes: an opinion on it that turns out right earns about 27 points, a wrong one costs about 73.